Once-daily maintenance bronchodilator to relieve symptoms and reduce exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).

Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active …

Ultibro Breezhaler is a medicine that contains two active substances, indacaterol (85 micrograms) and glycopyrronium (43 micrograms). It is used as maintenance (regular) treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults.

2024年11月8日 · Indacaterol and glycopyrrolate combination is used as long-term maintenance treatment of air flow blockage in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a long-term lung disease that causes bronchospasm (wheezing or difficulty with breathing).

2022年3月31日 · Pre-Metered Dose Dry Powder For Inhalation.

Indication/Uses: treatment to relieve symptoms and reduce exacerbations in adult patients with chronic obstructive pulmonary disease (COPD). This Medicine requires a physician's prescription.

Used as once-daily maintenance bronchodilator treatment to relieve symptoms &, reduce exacerbations in patients with COPD. 1 capsule once daily. Each capsule contains 143 micrograms indacaterol maleate equivalent to 110 micrograms indacaterol and 63 micrograms glycopyrronium bromide equivalent to 50 micrograms glycopyrronium.

Indication: Once-daily maintenance bronchodilator to relieve symptoms and reduce exacerbations in adult patients with chronic obstructive pulmonary disease (COPD). Generic Name: Indacaterol Maleate + Glycopyrronium Bromide Dosage Strength/Formulation: Indacaterol/glycopyrronium 110/50 microgram, inhalation powder in hard capsules.

Once-daily maintenance bronchodilator treatment to relieve symptoms and reduce exacerbations in adult patients with chronic obstructive pulmonary disease (COPD). The recommended dosage is the once-daily inhalation of the content of one inhaler.

Inhaled glycopyrrolate is a fast-acting, efficacious treatment option for patients with moderate–severe COPD. It improves lung function, reduces the risk of exacerbations, and alleviates the symptoms of breathlessness, which in turn may explain the improvement seen in patients’ quality of life.